Related Experiment Video
Updated: Sep 9, 2025

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
TGF-B-induced Cancer-associated Fibroblast Activation Promotes Tumor Progression In Oral Squamous Cell Carcinoma
Junya Hirota1, Daisuke Takeda2, Yasuaki Sadakane1
1Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Background/Aim:
Oral squamous cell carcinoma (OSCC) is a common malignancy with a poor prognosis, partly due to interactions within the tumor microenvironment. Cancer-associated fibroblasts (CAFs), key stromal components, promote tumor progression by enhancing cancer cell migration, angiogenesis, and extracellular matrix remodeling. Transforming growth factor-beta (TGF-β) is known to induce CAF differentiation from normal fibroblasts (NFs), but its functional contribution in OSCC remains to be fully elucidated. This study explored the role of TGF-β in inducing the transition of NFs into CAFs and its impact on progression of OSCC.
Materials And Methods:
In vitro, NFs were treated with TGF-β, and CAF induction was assessed by evaluating the expression of the CAF marker α-smooth muscle actin (α-SMA) using quantitative real-time PCR and fluorescent immunostaining. OSCC cell migration was analyzed using a scratch assay. In vivo, TGF-β-treated or untreated NFs were co-injected with OSCC cells. The tumor size and VEGF, MMP2, and MMP9 expression were analyzed via quantitative real-time PCR and immunohistochemistry.
Results:
In vitro, TGF-β-treated NFs exhibited significantly increased α-SMA expression and enhanced the OSCC migratory ability. In vivo, the TGF-β-treated group demonstrated a marked increase in tumor growth and up-regulated expression of VEGF, MMP2, and MMP9 compared to the untreated group.
Conclusion:
These findings suggest that TGF-β induces CAF differentiation and facilitates tumor progression by promoting angiogenesis and extracellular matrix degradation. This study highlights the potential of targeting TGF-β as a therapeutic strategy and underscores the need for novel approaches to counteract the tumor-promoting effects of CAFs.

